National Institute for Health and Care Excellence (NICE): Government against COVID-19 Non-funding Support
Entity: National Institute for Health and Care Excellence (NICE)
Category: Non-funding support
Description:
1. Project:
Nice Advice programme on COVID-19. NICE's advice programmes consists of a range of products that are either based on NICE guidance or involve a critical assessment of relevant evidence. However, these products do not have the status of formal NICE guidance, and do not contain new NICE recommendations.
2. project
NICE's Rapid evidence summaries on COVID
These summaries cover:
Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 - ES23.
Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis - ES26
Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 - ES24
Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 - ES25.
3. project
NICE's Medtech innovation briefings on COVID. Medtech innovation briefings (MIBs) are NICE advice. They are designed to support NHS and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies. The briefings will help avoid the need for organisations to produce similar information locally, saving staff time and resources. The information provided includes a description of the technology, how it’s used and its potential role in the treatment pathway. A MIB also includes a review of relevant published evidence and the likely costs of using the technologies. They are designed to be fast, flexible and responsive to the need for information on innovative technologies. MIBs are commissioned by NHS England and produced in support of the NHS 5-Year Forward View, specifically as one of a number of steps which will accelerate innovation in new treatments and diagnostics. These innovative technologies have been identified as being potentially useful during the COVID-19 pandemic.
Category: Non-funding support
Description:
1. Project:
Nice Advice programme on COVID-19. NICE's advice programmes consists of a range of products that are either based on NICE guidance or involve a critical assessment of relevant evidence. However, these products do not have the status of formal NICE guidance, and do not contain new NICE recommendations.
2. project
NICE's Rapid evidence summaries on COVID
These summaries cover:
Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 - ES23.
Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis - ES26
Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 - ES24
Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 - ES25.
3. project
NICE's Medtech innovation briefings on COVID. Medtech innovation briefings (MIBs) are NICE advice. They are designed to support NHS and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies. The briefings will help avoid the need for organisations to produce similar information locally, saving staff time and resources. The information provided includes a description of the technology, how it’s used and its potential role in the treatment pathway. A MIB also includes a review of relevant published evidence and the likely costs of using the technologies. They are designed to be fast, flexible and responsive to the need for information on innovative technologies. MIBs are commissioned by NHS England and produced in support of the NHS 5-Year Forward View, specifically as one of a number of steps which will accelerate innovation in new treatments and diagnostics. These innovative technologies have been identified as being potentially useful during the COVID-19 pandemic.
Technology:
COVID UK Funding&Support
Industry:
COVID UK Government
Headquarters:
United Kingdom
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Investor Type:
N/A
Investment Stage:
N/A
Number Of Exits:
N/A
Register and Claim Ownership